Stephen V Liu, MD
@StephenVLiu
Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Host @IASLC Podcast; Chair #DCLung24 #TexasLung24 #HereWeGo
21-09-2011 15:17:53
17,2K Tweets
23,9K Followers
3,0K Following
Pooled analysis of 5y outcomes with pembrolizumab + chemotherapy in PD-L1 negative NSCLC JTO & JTO CRR. Includes KEYNOTE 189, 407, and extension studies. With 60.7m f/u, addition of pembro to chemo improves OS (HR 0.64) & PFS (HR 0.66). 5y OS rate 12.5%.
jto.org/article/S1556-…